Novo Nordisk develops and sells pharmaceuticals, primarily for diabetes and hormone-related conditions.
SELECT trial data demonstrates cardioprotective benefit beyond weight loss, confirming GLP-1s as foundational preventive medicine; compounded GLP-1 price elasticity (15-20% market share at half price) reveals enormous latent demand.